Some biotechnology drugs have shown to be useful in the treatment of cancer patients. However, the majority present questionable efficacy, considerable adverse effects and are costly. It is convenient to demonstrate greater scientific rigor when approving or withdrawing these drugs. The public health services should consider selective financing of these drugs in terms of treatment benefits.

 Author:

• Juan Erviti. Drug Information Unit. Navarre Regional Health Service. Spain
  
  
  Link to the podcast and video (Spanish)

Entrevista a Rubén Pío (investigador del CIMA) y a Victoria González (abogada de una asociación de consumidores) sobre los fármacos biotecnológicos en oncología